Resverlogix AI Stock Analysis
Want to see TSE:RVX full AI Analyst Report?
Resverlogix (RVX) AI Stock Analysis
Resverlogix
(TSX:RVX)
The overall score is the minimum 37, reflecting a financially distressed, pre-revenue biotechnology company. The primary driver is the critical balance sheet, marked by negative equity and an unsustainable debt load, which poses an existential risk. This is compounded by a severe technical downtrend and a negative P/E ratio that confirms a lack of earnings. The company's survival is entirely dependent on securing additional financing.
Resverlogix (RVX) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 25.82M
- Dividend Yield
- ―
- Average Volume (3M)
- 31.34K
- Price to Earnings (P/E)
- -1.6
- Beta (1Y)
- 0.71
- Revenue Growth
- ―
- EPS Growth
- -28.45%
- Country
- Canada
- Employees
- 17
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Resverlogix Business Overview & Revenue Model
Company Description
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalon...
Resverlogix Financial Statement Overview
Summary
The company is pre-revenue with persistent operating losses and a critically distressed balance sheet. Negative equity of -$94.1M and a $77.6M debt load against minimal assets indicate technical insolvency. Cash flows are entirely negative, confirming complete reliance on external financing. The minor positive trend in narrowing operating losses is overshadowed by extreme leverage and existential liquidity risk.
Income Statement
1Very NegativeBalance Sheet
1Very NegativeCash Flow
1Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -421.65K | -437.53K | -476.75K | ― | 0 | 0 |
| EBITDA | -3.60M | -4.77M | -4.25M | -4.46M | -11.74M | -14.87M |
| Net Income | -10.84M | -7.90M | -7.63M | -16.74M | -3.61M | -24.77M |
Balance Sheet | ||||||
| Total Assets | 8.24M | 7.93M | 7.34M | 6.57M | 8.12M | 9.98M |
| Cash, Cash Equivalents and Short-Term Investments | 79.87K | 107.80K | 99.00K | 5,000 | 40.00K | 6,000 |
| Total Debt | 77.62M | 72.77M | 81.97M | 9.91M | 6.49M | 7.04M |
| Total Liabilities | 102.36M | 96.73M | 89.08M | 81.04M | 67.40M | 69.85M |
| Stockholders Equity | -94.12M | -88.80M | -81.73M | -74.47M | -59.28M | -59.87M |
Cash Flow | ||||||
| Free Cash Flow | -4.06M | -3.73M | -4.36M | -2.96M | -3.99M | -8.90M |
| Operating Cash Flow | -3.76M | -3.73M | -3.89M | -2.51M | -3.54M | -8.02M |
| Investing Cash Flow | -684.75K | -660.36K | -377.00K | -516.00K | -473.00K | -833.00K |
| Financing Cash Flow | 4.83M | 4.39M | 4.36M | 2.99M | 4.06M | 8.81M |
Resverlogix Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RVX, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.09, and below the 200-day MA of 0.10, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 46.52 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RVX.
Resverlogix Peers Comparison
Overall Rating
TSE:BCT53Neutral
TSE:MBX52Neutral
TSE:RVX37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 53Neutral | CAD 42.70M | -0.37 | -170.70% | ― | ― | 87.90% | |
| 52Neutral | CAD 40.41M | -8.36 | -18.83% | ― | -27.13% | -1752.63% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 37Underperform | CAD 25.82M | -1.63 | 10.92% | ― | ― | -28.45% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:RVX | Resverlogix Corp. | 0.07 | -0.03 | -25.00% | |
| TSE:BCT | BriaCell Therapeutics | 4.89 | -6.51 | -57.11% | |
| TSE:MBX | Microbix Biosystms | 0.29 | 0.04 | 18.00% | |
| TSE:GSD | Devonian Health Group, Inc. | 6.30 | -5.40 | -46.15% | |
| TSE:TTI | Thiogenesis Therapeutics Corp | 0.64 | -0.06 | -8.57% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
